Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Awaiting development
Reference number: GID-TA11100
Expected publication date: TBC
Following discussions with the company, the timelines for this appraisal have been rescheduled. The appraisal is expected to begin in mid-June 2026. Submissions are expected in mid-August 2026.